 Finding agents that are active against Klebsiella Pneumoniae Carbapenemase (KPC-producing bacteria with a highly drug-resistant gram-negative bacilli causing infections associated with significant morbidity and mortality)
 Recognizing that patients with complicated infections nowadays tend to be much sicker than they were 10 years ago, and physicians must closely monitor liver and kidney function  Finding antibiotics that will fit nursing home budgets  Having oral antibiotics so patients do not have to be hospitalized for an IV
Perceptions of the Streamlined Development Process
All of the physicians interviewed believe there is currently a crisis in this country in terms of antibiotic-resistant infections, since many strains of bacteria have become resistant to one or more antibacterial drugs. For some patients with multi-drugresistant infections, there may be no viable treatment options.
All of those interviewed thought that the Streamlined Development Program is an exciting approach to resolving this problem by bringing new antibiotics to market faster. Almost all believed that the benefits of antibiotics approved through this program outweigh the risks for critically ill patients who are out of options. The physicians said that the benefits given to the pharmaceutical companies for developing new antibacterials are appropriate and reasonable in order to incentivize development of new medications that will never be "blockbuster" drugs.
Other opinions the physicians expressed about the Streamlined Development Program include:
 The antibiotics that come out of the Streamlined Development Program should be used only for patients with unmet need, who are extremely ill with few or no other options.
 A majority of physicians would feel comfortable using a drug developed under this program, even with less data compared to drugs studied in the traditional review process.
 Physicians felt more confident knowing that the drugs would be approved by the FDA and thoroughly vetted by experts on their hospital pharmaceutical and therapeutics (P&T) committee. .  Familiarity with one or more of the drug's components would increase physicians' confidence.
 None would use antibiotics coming out of this program first line.
 Most would want to preserve the new drug for those with true unmet need even after the pathogens were identified.
 A few said they would rather use known drugs first because the new drugs would have limited data on efficacy and side effects, especially in the critically ill populations seen in ICUs. In contrast, others said that most of the antibiotics used to fight resistant infections have known, life-altering toxicities, e.g., renal failure, making most of the current known drugs suboptimal.
 The physicians' tolerance of uncertainty about risks increased as patients got sicker and had fewer options.
Perceptions of AVYCAZ: an example of a drug developed under the Streamlined Development Program
The physicians believed that a drug like AVYCAZ is a particularly apt example because it combines a known drug with another whose mechanism of action is fairly well-understood thus engendering fewer safety concerns than an entirely new class of antibiotics. The physicians said they would not use AVYCAZ first line. Even after cultures come back, none would use it, if there were alternatives. In this way AVYCAZ could be preserved for cases of true unmet need. Only a few physicians said they would feel somewhat uncomfortable using AVYCAZ for fragile patients because of the rapid approval process and limited data on how it would affect the very ill.
Additional information they would like to know before using AVYCAZ or any new antibiotic developed through a Streamlined Development process includes: 
Perceptions about ID consults
According to those interviewed, most ICU and ID physicians currently have very few restrictions on their authority to prescribe antibacterials. In fact, some said that either these physicians have "carte blanche" when it comes to prescribing or that there is not much enforceable oversight. All of those interviewed, however, strongly believe that there should be required ID consults for new antibacterials developed under the Streamlined Development Program. They further said that these consults shouldn't be with "just any ID, because in some cases, [the IDs] are part of the problem." They should be with either ID physicians who are on their hospital's antibiotic stewardship committee or who are experts in these new drugs. Some suggested that those IDs be required to obtain a special certification to qualify for giving these consults. The goal of the consult would be to assure that the new antibiotic was given only to appropriate candidates for it. This will preserve the drug from developing resistance and becoming "worthless in six months."
A few of the physicians said they wanted to make sure that ID consults wouldn't interfere with patients getting lifesaving antibiotics in time to have the best outcomes. In those cases the physicians said they would want a provision for the pharmacy to release several doses of the drug and to have an ID review 24 to 48 hours after the patient started taking the new antibiotic.
Reactions to the scenario
The physicians were given a scenario of a 58-year-old woman who presents with a complex infection after multiple recent hospital admissions, some necessitating antibiotic treatment. This woman is critically ill, with septic shock and perhaps a piperacillin-resistant gram-negative infection.
Most said that they would get new cultures at this point, and those who were not IDs/intensivenists said they also would arrange for an ID consult to guide their next steps. Some would consider increasing the dose of the medications she is taking. Others said they would re-broaden her antibiotic coverage while awaiting the culture results. Those physicians said they would switch her to a carbapenem, like imipenem or meropenem and possibly add amikacin or cefepime to the mix as well. None of those interviewed would not use AVYCAZ first line or even after the culture results came back, if other antibiotics would do the job.
Some of the physicians said they would consider giving AVYCAZ under the following circumstances:
 The patient was allergic to the other antibiotics that would address their pathogen(s).
 The known antibiotics are too risky in terms of toxicities.
 There were no other options that would be effective in combatting the identified pathogens, and the patient is in a life-or-death situation.
The physicians were then asked whether they would use AVYCAZ if this patient presented with hospital-or ventilator-acquired pneumonia. Most said that even with the same pathogen(s), they would be concerned about using AVYCAZ, unless they knew whether it had sufficient lung penetration.
Introduction
In June 2015, 23 in-depth telephone interviews were conducted on behalf of Clinical Trials Transformation Initiative (CTTI) with physicians who treat patients afflicted with complex bacterial infections. A mix of physicians were interviewed in both academic medicine (11) and community practice (12) in a variety of therapeutic specialty areas including:
Nine of those interviewed currently serve on their hospital's pharmacy and therapeutics (P&T) committees, which are tasked with reviewing all new drugs and deciding which ones to include on their formulary.
The overall objective of the interviews was to better understand physicians' decision-making process when treating critically ill patients with multi-drugresistant or hospital-acquired bacterial infections. In addition, the interviews sought to better understand provider perspectives about the advantages and disadvantages of an FDA streamlined development and approval process for new antibacterials.
All of the interviews were conducted by an experienced, professional moderator, and each lasted approximately 45 minutes to an hour. There was a great deal of consistency in the thinking and opinions of the physicians interviewed. The findings are presented below.
Detailed Findings

The most challenging aspects of treating patients with complicated infections
According to the physicians interviewed, one of their biggest challenges in treating complicated infections is treating patients who are extremely ill. These patients often have many comorbidities and have been on numerous antibiotics. Their underlying conditions and frequent hospitalizations make them fragile, and they are weakened further by their current serious infection. The physicians said that it is hard to predict how well these frail patients will be able to tolerate the strong and often toxic antibiotics available to treat resistant infections. In addition, they need to be closely monitored for changes in liver or kidney function. As these physicians explained:
" One of the biggest challenges in treating all patients with complicated infections is how to choose appropriate interim antibiotics until the offending pathogens are identified through cultures, which could take as long as 48 to 72 hours. Since time is of the essence, and better outcomes are associated with earlier treatment, the physicians typically treat patients empirically with their "best guess," until they receive the culture reports.
The physicians essentially follow a similar process for making these early-phase empirical treatment decisions. The general plan is to obtain specimens for cultures, then initiate a course of broad-spectrum antibiotics to cover most of the bases while they wait for the culture results. The physicians said that it is easier to make medication decisions for patients from their own institutions because the pathogens which colonize their hospital environment are known, giving them a good starting point for choosing empirical antibiotics. If they suspect other pathogens, they will add coverage for those.
For those patients from other environments, e.g., nursing homes, rehabilitation facilities or distant hospitals, choosing antibiotics that will treat the probable pathogens is not as clear and that sometimes they "guess wrong." In those cases, physicians try to gather as much information as possible about the patient's medical history, particularly prior infections and medications they have taken, to guide and inform the initial choice of antibiotics. When possible, they rely on family members to provide this background information. Once the cultures come back and sensitivities are identified, they de-escalate the coverage to drugs directed to the specific pathogen(s) identified.
Some of the physicians described this process for making pre-culture treatment decisions for their critically ill patients with serious infections like this: 2) Getting antibiotics to patients in a timely fashion, especially at night when pharmacy staffing is low and the overwhelmed pharmacists must cover the entire hospital, not just the ICU 3) Finding agents that are active against Klebsiella Pneumoniae Carbapenemase (KPC-producing bacteria with a highly drug-resistant gram-negative bacilli causing infections associated with significant morbidity and mortality) 4) Recognizing that patients with complicated infections nowadays tend to be much sicker than they were 10 years ago, and physicians must be on their toes monitoring their liver and kidney function 5) Finding antibiotics that will fit nursing home budgets
Physician communication with the patient and their family members
According to the physicians interviewed, the patients with resistant infections are typically too ill to take a meaningful part in a discussion about their condition, and family members are not medically savvy enough to weigh in on the choice of antibiotics in such complicated medical scenarios. The physicians do, however, have discussions with family members about their loved ones' condition and generally share their thinking about the treatment plan. They usually communicate in layman's terms about the patient's infection and the medications they will use to treat it.
In these situations, the role of the family members is more to provide the physicians with critical information that will help them make the best empirical treatment decisions while waiting for the culture results. This is especially true in cases in which the patients are coming from another institution, e.g., a rehab center or long-term care facility, and little is known about their previous infections and medication history. These physicians described their usual interactions with the family members like this: 
Defining "unmet medical need"
In preparation for the discussion about the FDA streamlined development and approval process for antibacterials, the physicians were asked how they would define the term "unmet medical need" when referring to bacterial infections. Some described it this way: 
Reactions to the concept of the streamlined development program
The physicians were asked to read and react to a background piece on the antibiotic-resistance crisis and shortened drug development and review programs that would enable critically ill patients with few or no other options to receive potentially lifesaving antibiotics early, with the understanding that the usual testing and review process had been shortened. All said that they were in favor of such programs, in light of the severity of the current situation of antibiotic resistance. All believed that the benefits of such a program outweigh the disadvantages in cases where there is true unmet need and no other good options. As these physicians said: The physicians interviewed said that they would feel comfortable using drugs developed under the program if they had no other option, or if the only available options have high toxicity. A few said that they would have more confidence using a streamlined development drug once it was approved by their P&T committee, since that process is typically rigorous:
"Before this drug would get on our formulary, it would be thoroughly studied by our P&T committee and thoroughly vetted through the infectious-disease service. So if a drug ends up on our formulary, whether it's limited or not limited, I'm pretty confident that good people -both physicians and pharmacologists -have looked at it and are comfortable putting it on our list of drugs. I'm OK with anything that ends up on our formulary."
Similarly, some said that having FDA approval, would make them comfortable prescribing it, even through it was approved through a streamlined process One of the biggest concerns among the physicians is that the data available about drugs developed through a streamlined development program would not be on very ill patients like most of those they would be using these drugs to treat. In addition, figuring the correct dosage would be especially difficult for patients on continual dialysis, since it would be difficult to calculate how much of the drug they are actually getting. Many of the physicians said they would like more information about these drugs once they have been used with actual patients:
"I'm excited about having new products to use, because I face this problem a couple times a month when I have a patient who has a resistant infection, and it comes to having to use toxic medications. But the Phase II trial data [of drugs developed under the streamlined program] doesn't cover the kinds of patients I see. I want to know how it would do with real-world patients who need this drug -the frail patients who may be on dialysis or on continual dialysis. How will they do?"
According to some of the physicians, key to helping physicians feel comfortable with streamlined development antibiotics is gathering data from clinical use with real-life patients and making those findings available. A few of the physicians thought that FDA should make this a required part of the approval process for pharmaceutical companies to disclose data gathered from using new antibiotics approved through a streamlined development program. They said that they would like to see this data as the drug is being used in clinical as opposed to research settings. A few said they would like to get this kind of information through a neutral party such as a professional organization they trust like the Infectious Disease Societies of America (IDSA). They suggested that that FDA and the IDSA sponsor informational talks and a website as the new antibiotics are being rolled out, letting doctors know that FDA is going to approve these drugs and review them regularly and make the data transparent with a partner that the ID community can trust: IDSA.
Expert consults when making antibiotic treatment decisions with antibacterials developed under a Streamlined Development Program
According to the physicians interviewed, most ICU and ID physicians have very few restrictions on their authority to prescribe antibacterials. In fact, some said that either these physicians have "carte blanche" when it comes to prescribing, or that there is not much enforceable oversight. When it comes to physicians on the floor, however, limits are more regularly enforced. As some of the physicians described it:
" 
Perceptions of AVYCAZ
The physicians interviewed were given a press release announcing the February 2015 approval of AVYCAZ as an example of a real-life antibiotic that was recently approved under the FDA's Streamlined Development Program. They also read a
